Search

RU-2026110956-A - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT, PREVENTION AND/OR DIAGNOSIS OF MALIGNANT TUMOR

RU2026110956ARU 2026110956 ARU2026110956 ARU 2026110956ARU-2026110956-A

Inventors

  • МАДЗИМА, Юки
  • ОКАНО, Фумиёси

Assignees

  • ТОРЭЙ ИНДАСТРИЗ, ИНК.

Dates

Publication Date
20260505
Application Date
20240912
Priority Date
20230913

Claims (20)

  1. 1. A complex wherein the radioisotope(s) and an antibody or fragment thereof having immunological reactivity with respect to the CAPRIN-1 protein having an amino acid sequence presented under any of the even SEQ ID NOs: 2-30, or an amino acid sequence having 80% or more sequence identity with this amino acid sequence, are linked via a chelating agent(s).
  2. 2. The complex according to claim 1, wherein the antibody or fragment thereof has immunological reactivity with respect to a partial polypeptide of the CAPRIN-1 protein and wherein the partial polypeptide has an amino acid sequence presented under any of SEQ ID NOs: 31-35, 296-299, 308 and 309, or an amino acid sequence having 80% or more sequence identity with this amino acid sequence.
  3. 3. The complex according to claim 1, wherein the antibody is a monoclonal antibody or a polyclonal antibody.
  4. 4. The complex of claim 1, wherein the antibody or fragment thereof is any of the following (A)-(M):
  5. (A) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 36, 37 and 38 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 40, 41 and 42 (CDR1, CDR2 and CDR3, respectively) and having immunological reactivity with respect to the CAPRIN-1 protein;
  6. (B) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 44, 45 and 46 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 48, 49 and 50 (CDR1, CDR2 and CDR3, respectively) and having immunological reactivity with respect to the CAPRIN-1 protein;
  7. (C) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 52, 53 and 54 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 56, 57 and 58 (CDR1, CDR2 and CDR3, respectively) and having immunological reactivity with respect to the CAPRIN-1 protein;
  8. (D) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 60, 61 and 62 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 64, 65 and 66 (CDR1, CDR2 and CDR3, respectively) and having immunological reactivity with respect to the CAPRIN-1 protein;
  9. (E) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 170, 171 and 172 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 173, 174 and 175 (CDR1, CDR2 and CDR3, respectively) and having immunological reactivity with respect to the CAPRIN-1 protein;
  10. (F) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 176, 177 and 178 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 179, 180 and 181 (CDR1, CDR2 and CDR3, respectively) and having immunological reactivity with respect to the CAPRIN-1 protein;
  11. (G) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 182, 183 and 184 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 185, 186 and 187 (CDR1, CDR2 and CDR3, respectively) and having immunological reactivity with respect to the CAPRIN-1 protein;
  12. (H) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 188, 189 and 190 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 191, 192 and 193 (CDR1, CDR2 and CDR3, respectively) and having immunological reactivity with respect to the CAPRIN-1 protein;
  13. (I) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 146, 147 and 148 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 149, 150 and 223 (CDR1, CDR2 and CDR3, respectively) and having immunological reactivity with respect to the CAPRIN-1 protein;
  14. (J) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 272, 273 and 274 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 275, 276 and 277 (CDR1, CDR2 and CDR3, respectively), and having immunological reactivity with respect to the CAPRIN-1 protein;
  15. (K) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 290, 291 and 292 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 293, 294 and 295 (CDR1, CDR2 and CDR3, respectively), and having immunological reactivity with respect to the CAPRIN-1 protein;
  16. (L) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NOs: 300, 301, and 302 (CDR1, CDR2, and CDR3, respectively), and a light chain variable region comprising the complementarity determining regions of SEQ ID NOs: 304, 305, and 306 (CDR1, CDR2, and CDR3, respectively), and having immunological reactivity with respect to the CAPRIN-1 protein; and
  17. (M) an antibody or fragment thereof comprising a heavy chain variable region comprising the complementarity determining regions of SEQ ID NO: 134, 135 and 136 (CDR1, CDR2 and CDR3, respectively) and a light chain variable region comprising the complementarity determining regions of SEQ ID NO: 137, 138 and 139 (CDR1, CDR2 and CDR3, respectively), and having immunological reactivity with respect to the CAPRIN-1 protein.
  18. 5. The complex of claim 1, wherein the antibody or fragment thereof is any of the following (a) through (al):
  19. (a) an antibody or fragment thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 39 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 43;
  20. (b) an antibody or fragment thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 47 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 51;